Mirikizumab (LY3074828) is a humanized IgG4 monoclonal antibody specifically designed to target the p19 subunit of interleukin 23 (IL-23). This antibody demonstrates high affinity binding to IL-23 in both human and monkey models, with dissociation constants (Kd) of 21 pM and 55 pM, respectively. By selectively inhibiting the interaction between IL-23 and its receptor IL-23R, Mirikizumab effectively modulates the immune response. This mechanism of action suggests its utility in exploring therapeutic avenues for inflammatory bowel diseases such as ulcerative colitis and Crohn's disease in research settings.
Mirikizumab (LY3074828) is a humanized IgG4 monoclonal antibody specifically designed to target the p19 subunit of interleukin 23 (IL-23). This antibody demonstrates high affinity binding to IL-23 in both human and monkey models, with dissociation constants (Kd) of 21 pM and 55 pM, respectively. By selectively inhibiting the interaction between IL-23 and its receptor IL-23R, Mirikizumab effectively modulates the immune response. This mechanism of action suggests its utility in exploring therapeutic avenues for inflammatory bowel diseases such as ulcerative colitis and Crohn's disease in research settings.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula: